CSPC Pharmaceutical Group Limited
CSPCY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $30,867,889 | $34,599,374 | $35,012,349 | $34,188,155 |
| % Growth | -10.8% | -1.2% | 2.4% | – |
| Cost of Goods Sold | $9,268,631 | $10,202,020 | $8,863,817 | $8,113,210 |
| Gross Profit | $21,599,258 | $24,397,354 | $22,726,458 | $25,472,247 |
| % Margin | 70% | 70.5% | 64.9% | 74.5% |
| R&D Expenses | $5,523,224 | $5,337,555 | $4,578,571 | $4,215,031 |
| G&A Expenses | $1,148,774 | $1,308,774 | $1,327,345 | $1,238,891 |
| SG&A Expenses | $10,366,077 | $11,364,727 | $13,026,559 | $14,051,286 |
| Sales & Mktg Exp. | $9,217,304 | $10,055,954 | $11,699,214 | $12,812,394 |
| Other Operating Expenses | $0 | $14,949 | $0 | $0 |
| Operating Expenses | $15,889,301 | $16,717,231 | $17,605,130 | $18,266,317 |
| Operating Income | $5,709,957 | $7,680,123 | $7,583,213 | $7,663,035 |
| % Margin | 18.5% | 22.2% | 21.7% | 22.4% |
| Other Income/Exp. Net | $226,200 | -$290,751 | $997,891 | $737,248 |
| Pre-Tax Income | $5,936,157 | $7,389,372 | $8,581,103 | $8,400,282 |
| Tax Expense | $1,319,342 | $1,316,679 | $1,350,211 | $1,421,872 |
| Net Income | $4,605,334 | $5,873,325 | $6,893,834 | $6,876,658 |
| % Margin | 14.9% | 17% | 19.7% | 20.1% |
| EPS | 1.56 | 2 | 2.04 | 1.88 |
| % Growth | -22% | -2% | 8.5% | – |
| EPS Diluted | 1.56 | 2 | 2.04 | 1.88 |
| Weighted Avg Shares Out | 2,934,667 | 2,968,125 | 2,979,301 | 2,988,372 |
| Weighted Avg Shares Out Dil | 2,934,511 | 2,968,258 | 2,979,631 | 2,988,460 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $43,673 | $25,896 | $24,891 | $7,664 |
| Depreciation & Amortization | $1,154,554 | $1,117,490 | $1,047,939 | $1,041,003 |
| EBITDA | $6,864,511 | $8,532,758 | $8,655,091 | $9,275,387 |
| % Margin | 22.2% | 24.7% | 24.7% | 27.1% |